Heron Stock Analysis

HRTX -  USA Stock  

USD 8.89  0.36  4.22%

The big decline in price over the last few months for Heron Therapeuticsmay raise some interest from investors. The stock closed today at a share price of 8.89 on 3,030,100 in trading volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Heron Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.93. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Heron Therapeutics partners.
Please check Risk vs Return Analysis.

Heron Stock Analysis 

The Heron Therapeutics stock analysis report makes it easy to digest most publicly released information about Heron Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Heron Stock analysis module also helps to analyze the Heron Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Heron Stock Analysis Notes

About 109.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.38. Heron Therapeutics had not issued any dividends in recent years. The entity had 1:20 split on the 13th of January 2014. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 223 people. To learn more about Heron Therapeutics call Barry Quart at 858 251-4400 or check out www.herontx.com.

Heron Therapeutics Quarterly Cost of Revenue

11.35 MillionShare

Heron Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Heron Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Heron Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Heron Therapeutics generated a negative expected return over the last 90 days
Heron Therapeutics has high historical volatility and very poor performance
Heron Therapeutics has a very high chance of going through financial distress in the upcoming years
Heron Therapeutics was previously known as Heron Therapeutics and was traded on NASDAQ Exchange under the symbol APPA.
The company reported the previous year's revenue of 86.3 M. Net Loss for the year was (228.32 M) with loss before overhead, payroll, taxes, and interest of (120.88 M).
Heron Therapeutics currently holds about 202.82 M in cash with (210.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.99.
Heron Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from simplywall.st: Health Check How Prudently Does Heron Therapeutics Use Debt - Simply Wall St

Heron Therapeutics Upcoming and Recent Events

Earnings reports are used by Heron Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Heron Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Earnings Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Heron Largest EPS Surprises

Earnings surprises can significantly impact Heron Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Heron Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Heron Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Heron Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Heron Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
24th of January 2022
Unclassified Corporate Event
9th of December 2021
Financial Statements and Exhibits. Other Events
18th of November 2021
Financial Statements and Exhibits. Other Events
3rd of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
4th of October 2021
Financial Statements and Exhibits. Other Events
24th of September 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
9th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of August 2021
Financial Statements and Exhibits. Changes in Registrant's Certifying Accountant

Heron Therapeutics Thematic Classifications

In addition to having Heron Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Heron Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 906.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Heron Therapeutics's market, we take the total number of its shares issued and multiply it by Heron Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Heron Profitablity

Heron Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Heron Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Heron Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Heron Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Heron Therapeutics' profitability requires more research than a typical breakdown of Heron Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (264.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (254.92) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.55.
Last ReportedProjected for 2022
Return on Investment(62.89) (67.86) 
Return on Average Assets(0.63) (0.68) 
Return on Average Equity(0.68) (0.73) 
Return on Invested Capital(0.84) (0.86) 
Return on Sales(2.97) (3.21) 

Management Efficiency

The entity has return on total asset (ROA) of (37.04) % which means that it has lost $37.04 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (115.32) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeutics management efficiency ratios could be used to measure how well heron therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to drop to -67.86 in 2022. Return on Average Assets is likely to drop to -0.68 in 2022. Heron Therapeutics Assets Non Current are fairly stable at the moment as compared to the past year. Heron Therapeutics reported Assets Non Current of 45.26 Million in 2021. Net Current Assets as percentage of Total Assets is likely to rise to 75.42 in 2022, whereas Total Assets are likely to drop slightly above 329.6 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 3.00  3.41 
Enterprise Value over EBIT(7.20) (7.77) 
Enterprise Value over EBITDA(7.37) (7.95) 
Price to Book Value 9.35  10.09 
Tangible Assets Book Value per Share 4.48  4.80 
Enterprise Value2.1 B2.3 B
Tangible Asset Value406.6 M329.6 M

Technical Drivers

As of the 26th of January, Heron Therapeutics retains the market risk adjusted performance of (0.25), and Risk Adjusted Performance of (0.08). Heron Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Heron Therapeutics, which can be compared to its competitors. Please check out Heron Therapeutics variance and potential upside to decide if Heron Therapeutics is priced fairly, providing market reflects its last-minute price of 8.89 per share. Given that Heron Therapeutics has jensen alpha of (0.09), we strongly advise you to confirm Heron Therapeutics's regular market performance to make sure the company can sustain itself at a future point.

Heron Therapeutics Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixteen. The Simple Moving Average indicator is calculated by adding the closing price of Heron Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Heron Therapeutics short-term fluctuations and highlight longer-term trends or cycles. View also all equity analysis or get more info about simple moving average overlap studies indicator.

Heron Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heron Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heron Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Heron Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Peraza Lisa over a week ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 1933 shares of Heron Therapeutics subject to Rule 16b-3
Dissanaike Sharmila over a month ago via Macroaxis 
Acquisition by Dissanaike Sharmila of 20903 shares of Heron Therapeutics subject to Rule 16b-3
Craig Johnson over a month ago via Macroaxis 
Acquisition by Craig Johnson of 10452 shares of Heron Therapeutics subject to Rule 16b-3
Barry Quart over a month ago via Macroaxis 
Payment of 963 shares by Barry Quart of Heron Therapeutics subject to Rule 16b-3
Peraza Lisa over three months ago via Macroaxis 
Acquisition by Peraza Lisa of 23424 shares of Heron Therapeutics subject to Rule 16b-3
Dissanaike Sharmila over three months ago via Macroaxis 
Heron Therapeutics exotic insider transaction detected
Christian Waage over three months ago via Macroaxis 
Sale by Christian Waage of 300 shares of Heron Therapeutics
Peraza Lisa over six months ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 552 shares of Heron Therapeutics subject to Rule 16b-3
Christian Waage over six months ago via Macroaxis 
Sale by Christian Waage of 300 shares of Heron Therapeutics
Kimberly Manhard over six months ago via Macroaxis 
Sale by Kimberly Manhard of 1529 shares of Heron Therapeutics
Christian Waage over six months ago via Macroaxis 
Sale by Christian Waage of 300 shares of Heron Therapeutics
Peraza Lisa over six months ago via Macroaxis 
Exercise or conversion by Peraza Lisa of 552 shares of Heron Therapeutics subject to Rule 16b-3

Heron Therapeutics Predictive Daily Indicators

Heron Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Heron Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Heron Therapeutics Forecast Models

Heron Therapeutics time-series forecasting models is one of many Heron Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Heron Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Heron Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Heron Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Heron shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Heron Therapeutics. By using and applying Heron Stock analysis, traders can create a robust methodology for identifying Heron entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(2.93) (3.16) 
Gross Margin 0.53  0.61 
Profit Margin(2.95) (3.18) 
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 223 people.

Current Heron Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Heron analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Heron analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
33.0Strong Buy5Odds
Heron Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Heron analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Heron stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Heron Therapeutics, talking to its executives and customers, or listening to Heron conference calls.
Heron Analyst Advice Details

Heron Stock Analysis Indicators

Heron Therapeutics stock analysis indicators help investors evaluate how Heron Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Heron Therapeutics shares will generate the highest return on investment. By understating and applying Heron Therapeutics stock analysis, traders can identify Heron Therapeutics position entry and exit signals to maximize returns.
Quick Ratio3.40
Fifty Two Week Low7.85
Revenue Growth16.40%
Shares Short Prior Month30.79M
Average Daily Volume Last 10 Day1.97M
Average Daily Volume In Three Month2.09M
Shares Percent Shares Out33.33%
Gross Margins-119.79%
Short Percent Of Float38.12%
Forward Price Earnings-4.54
Float Shares72.68M
Fifty Two Week High20.45
Enterprise Value To Ebitda-4.42
Fifty Day Average9.39
Two Hundred Day Average12.32
Enterprise Value To Revenue11.11
Please check Risk vs Return Analysis. Note that the Heron Therapeutics information on this page should be used as a complementary analysis to other Heron Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Heron Stock analysis

When running Heron Therapeutics price analysis, check to measure Heron Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeutics is operating at the current time. Most of Heron Therapeutics' value examination focuses on studying past and present price action to predict the probability of Heron Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heron Therapeutics' price. Additionally, you may evaluate how the addition of Heron Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bond Directory
Find actively traded corporate debentures issued by US companies
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Heron Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeutics. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heron Therapeutics is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeutics' market value can be influenced by many factors that don't directly affect Heron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heron Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.